Corvus Pharmaceuticals, Inc. (CRVS) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US2210151005
Corvus Pharmaceuticals, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -42.97 m USD |
| EBIT | -15.28 m USD |
| Net income | -15.28 m USD |
| Diluted EPS – continuing operations | -0.53 USD |
Full history since 2014, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the United States. The company's lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1b/2 clinical trial for the treatment of peripheral T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, autoimmune lymphoproliferative syndrome, and solid tumors monotherapy, and asthma, diseases. It also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of first line renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1 clinical trial for the treatment of non-small cell lung cancer. It has a license agreement with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as license agreement with Scripps for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in South San Francisco, California.
More stocks
- JW Pharmaceutical Corp (001067.KS)
- Yonyou Auto Information Technology (Shanghai) Co. Ltd. (688479.SS)
- Hangzhou Star Shuaier Electric Appliance Co Ltd (002860.SZ)
- COLLEGIUM PHARMACEUTICAL, INC (COLL)
- Nextdoor Holdings, Inc. (NXDR)
- KRONOS WORLDWIDE INC (KRO)
- Riley Exploration Permian, Inc. (REPX)
- Sinostone Guangdong Co Ltd (001212.SZ)
- Jinxin Fertility Group Ltd (1951.HK)
- Caisse Regionale de Credit Agricole Mutuel de Normandie Seine SC (CCN.PA)
- SK Networks Co Ltd (001740.KS)
- Voyager Technologies, Inc./TX (VOYG)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.